Declaratory Order: Resolution of Shortages of Tirzepatide Injection Products
FDA determined that the national shortage of tirzepatide injection products (Mounjaro and Zepbound) was resolved and provided 60/90-day enforcement-discretion transition periods for compounders.
Not legal or medical advice.
This page is for informational purposes only. Always verify the current official source or consult a qualified professional before making compliance, prescribing, purchasing, or clinical decisions. Read full disclaimer.
U.S. Food and Drug AdministrationDeclaratory orderEffective
- Docket / Citation
- Drug Shortages
- Published
- 2024-12-19
- Effective
- 2024-12-19